Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 1141

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 9B
Chunk 1141
---
 from the commencement of sales of the offering) and customary
anti-dilution provisions as permitted under FINRA Rule 5110(g)(8).

Key
assumptions used to value underwriter warrants in August 2023 were as follows:

Schedule
of Key Assumptions Used to Value Underwriter Warrants

    Expected
    price volatility 
     98.53%
  
    Risk-free
    interest rate 
     4.16%
  
    Fair
    Market Value of underlying Common Stock 
    $5.297 
  
    Expected
    Term in years 
     5
                                            years 
  
    Dividend
    yield 
     - 

    F-20

MIRA PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

DECEMBER 31, 2024 AND 2023

Note
9. Segment Information

The
Company operates in one reportable segment related to the development and commercialization of pharmaceuticals targeting neurologic and
neuropsychiatric disorders. The CODM for the Company is the Chief Executive Officer (the “CEO”). The Company’s CEO
reviews operating results on an aggregate basis and manages the Company’s operations as a whole for the purpose of evaluating financial
performance and allocating resources. Accordingly, the Company has determined that it has a single reportable and operating segment structure.
The CEO uses aggregate net loss to allocate resources in the annual budgeting and forecasting process and also uses that measure as a
basis for evaluating financial performance regularly by comparing actual results with established budgets and forecasts.

The
accounting policies of the Company’s single segment are the same as those described in the summary of significant accounting policies
within Note 1. The CEO assesses performance for the Company and decides how to allocate resources based on the aggregate net loss that
is also reported on the income statement as net loss. The measure of segment assets is reported on the balance sheets as total assets.

The
table below provides information about the Company’s revenue, significant segment expenses and other segment expenses.

 Schedule
of Segment Expenses and Other Segment Expenses

    2024  
    2023 

    Years Ended December 31, 

    2024  
    2023 
  
    Revenues 
    $—  
    $— 
  
    Less segment expenses: 

    Research and development 
     3,305,575  
     1,572,962